Amgen tax hit lowers net income 74 percent for 2017
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen lawsuit over cholesterol drug will get new trial
An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →
Amgen partnering to develop new drugs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FDA gives full approval to Amgen leukemia drug Blincyto
Amgen’s leukemia drug Blincyto received full approval from the U.S. Food and Drug Administration on July 11 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. The biotech giant, headquartered in Thousand Oaks, had previously announced that the drug had been fast-tracked for priority review. The full approval includes data Read More →
FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease
The U.S. Food and Drug Administration approved Amgen’s Parsabiv drug to treat patients with chronic kidney disease, the company announced on Feb. 7. The Thousand Oaks-based biotech company’s Parsabiv is the first therapy approved for the treatment of secondary hyperparathyroidism for patients on hemodialysis in 12 years, Amgen said. “We are excited about today’s approval Read More →
Settlement ends Amgen drug kickback saga
A drug kickback program is finally behind Amgen, the Thousand Oaks-based pharmaceutical giant. Louisville, K.Y.-based PharMerica was the last of three companies to settle lawsuits relating to Amgen allegedly paying kickbacks to PharMerica and another company to prescribe patients the anemia drug Aranesp. PharMerica settled the suit for $2.5 million in December, Louisville Business First Read More →
